FIG. 5.
Enhanced in vitro proliferative responses in c-FLIPL Tg mice. (A) Purified lymph node T cells from c-FLIPL Tg mice and NLC were activated with the indicated concentrations of plate-bound anti-CD3 or phorbol myristate acetate (1 ng/ml) and ionomycin (0.5 μM) for 6 days. [3H]thymidine (0.5 μCi/well) was added during the final 16 h of culture. (B) Purified lymph node T cells from c-FLIPL Tg mice and NLC were activated with a high (0.2-μg/ml) or suboptimal (0.04-μg/ml) dose of plate-bound anti-CD3 for the indicated number of days, and [3H]thymidine (0.5 μCi/well) was added during the final 16 h of culture. (C) Purified lymph node T cells of NLC and Tg mice derived from the second c-FLIPL Tg line (Tg 2) were stimulated with suboptimal doses of anti-CD3 for 4 days, and [3H]thymidine was added during the final 16 h of culture. (D) Total lymph node cells and FACS-sorted CD4+ and CD8+ T cells were stimulated with a suboptimal dose of plate-bound anti-CD3 (0.04 μg/ml) for 4 days, and [3H]thymidine was added during the final 16 h of culture. (E) Purified lymph node T cells were stimulated with 0.04 μg of plate-bound anti-CD3/ml, and IL-2 production was measured in 24-h culture supernatants. (F) Purified lymph node T cells were stimulated with 0.04 μg of plate-bound anti-CD3/ml in the presence or absence of IL-2 for 4 days, and [3H]thymidine was added during the final 16 h of culture. (G) Purified lymph node T cells were stimulated for 4 days with a low dose of coated anti-CD3 (0.04 μg/ml) in the presence or absence of a blocking anti-IL-2R MAb (10 μg/ml). [3H]thymidine was added during the final 16 h of culture.